EL7.AI 上提供的信息仅供教育和参考目的，不构成财务建议。
Rhythm Pharmaceuticals' shares dropped after its experimental drug for rare genetic obesity failed to meet the primary goal of its late-stage clinical trial. Meanwhile, rival drugs achieved significant weight loss results, leading to major shifts in the obesity and diabetes drug market. Novo Nordisk's Wegovy® HD received FDA approval, showing remarkable weight loss outcomes.